Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient
Open accessThe DOI matches its Crossref record; 166 of the 167 references it cites were found in a registry or an index.
Abstract
Major depressive disorder is an often chronic and recurring illness. Left untreated, major depressive disorder may result in progressive alterations in brain morphometry and circuit function. Recent findings, however, suggest that pharmacotherapy may halt and possibly reverse those effects. These findings, together with evidence that a delay in treatment is associated with poorer clinical outcomes, underscore the urgency of rapidly treating depression to full recovery. Early optimized treatment, using measurement-based care and customizing treatment to the individual patient, may afford the best possible outcomes for each patient. The aim of this article is to present recommendations for using a patient-centered approach to rapidly provide optimal pharmacological treatment to patients with major depressive disorder. Offering major depressive disorder treatment determined by individual patient characteristics (e.g., predominant symptoms, medical history, comorbidities), patient preferences and expectations, and, critically, their own definition of wellness provides the best opportunity for full functional recovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This dysfunction contributes to compulsive actions by reinforcing rigid, maladaptive response patterns that resist modification, thereby reducing cognitive flexibility, particularly in contexts involving task shifts, feedback adaptation, or updating based on new information (13, 21, 172).”
From Neural mechanisms underlying cognitive inflexibility in obsessive-compulsive disorder: a review (2026) · cites this paper as [172]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988 · cited 1×
“In addition to mood symptoms, individuals with MDD experience impairments in physical, occupational, and social functioning (Kessler et al., 2003; American Psychiatric Association, 2013).”
BackgroundOsterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
The PHQ-9: A New Depression Diagnostic and Severity Measure
Kroenke, K., & Spitzer, R. L. (2002) · Psychiatric Annals · doi:10.3928/0048-5713-20020901-06 · Cited by 5,898 · cited 11×
“Guideline-based validated instruments such as the PHQ-9 or Quick Inventory of Depressive Symptomatology, in contrast, are fast, easy, and self-administered (Kroenke and Spitzer, 2002; Rush et al., 2006a; Thase, 2014b).”
BackgroundMethodInfluentialRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Kirk, J., MacDonald, A., Lavender, P., Dean, J., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,887
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
KESSLER, R. C., ADLER, L., AMES, M., DEMLER, O., FARAONE, S., HIRIPI, E., HOWES, M. J., JIN, R., SECNIK, K., SPENCER, T., et al. (2005) · Psychological Medicine · doi:10.1017/s0033291704002892 · Cited by 3,452 · cited 2×
“, 2012), the authors recommend assessing for ADHD using the Adult ADHD Self-Report Scale (Kessler et al., 2005) in patients with treatment-resistant depression.”
MethodAssessment of social adjustment by patient self report.
Weissman, M. M. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770090101010 · Cited by 1,782 · cited 1×
“…7 scored on a 5-point, Likert scale Lam et al., 2009) Social Adjustment Scale, Self-Report Version 48 items in 6 domains, each rated on a 5-point, Likert scale Weissman and Bothwell, 1976 Social and Occupational Functioning Assessment Scale Single scale, scored 0–100 Rybarczyk, 2011 EuroQoL-5D…”
Method
Research works printed but not linked: 5
- American Psychiatric Association, 2013, Major depressive disorder, 160
- Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA), 2011, Canadian ADHD Practice Guidelines
- Canadian Network for Mood and AnxietyTreatments, 2017, SwitchRx: switching antipsychotic medications
- Sheehan, 2000, Sheehan Disability Scale, 113
- Work Group on Major Depressive Disorder. Practice Guideline For the Treatment of Patients With Major Depressive Disorder, edition 3. American Psychiatric Association, 2010
Cited by
Sajjadian, M., Lam, R. W. M., Milev, R. V., Rotzinger, S., Frey, B. N., Soares, C. N., Parikh, S. V., Foster, J. A., Turecki, G., Müller, D. J., et al. (2021) · Psychological Medicine · doi:10.1017/s0033291721003871 · Cited by 183
“If we could predict response to a specific treatment from individual characteristics, we could reduce the duration of depression and improve long-term functional outcomes (Oluboka et al., 2018).”
BackgroundSelf-citationKasper, S., Cubała, W. J., Fagiolini, A., Ramos-Quiroga, J. A., Souery, D., & Young, A. H. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1836399 · Cited by 85
Improving Depression Outcome by Patient-Centered Medical Management
Rush, A. J., & Thase, M. E. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18040398 · Cited by 76
New trends in personalized treatment of depression
Sampogna, G., Toni, C., Catapano, P., Rocca, B. D., Vincenzo, M. D., Luciano, M., & Fiorillo, A. (2023) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000903 · Cited by 88
“The definition of functional recovery includes a condition in which the patient starts to enjoy again his/her usual activities, returns to work and is able to take care of him/herself [10].”
BackgroundHogg, B., Medina, J. C., Gardoki-Souto, I., Serbanescu, I., Moreno‐Alcázar, A., Pashoja, A. C., Coppens, E., Tóth, M. D., Fanaj, N., Greiner, B. A., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.04.071 · Cited by 80
“Prevention, early recognition and treatment of anxiety and depressive disorders are crucial aspects in improving prognosis (Craske and Stein, 2016; Kraus et al., 2019; Olobuka et al., 2018).”
BackgroundJain, S., Gupta, S., Li, V. W., Suthoff, E., & Arnaud, A. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04165-x · Cited by 53
Emotional blunting in patients with depression. Part I: clinical characteristics
Christensen, M. C., Ren, H., & Fagiolini, A. (2022) · Annals of General Psychiatry · doi:10.1186/s12991-022-00387-1 · Cited by 53
Minelli, A., Zampieri, E., Sacco, C., Bazzanella, R., Mezzetti, N., Tessari, E., Barlati, S., & Bortolomasi, M. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.01.070 · Cited by 53
Mattingly, G. W., Ren, H., Christensen, M. C., Katzman, M. A., Polosan, M., Simonsen, K., & Hammer-Helmich, L. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.824831 · Cited by 47
Self-citationEconomic burden of relapse/recurrence in patients with major depressive disorder
Gauthier, G., Mucha, L., Shi, S., & Guerin, A. (2019) · Journal of Drug Assessment · doi:10.1080/21556660.2019.1612410 · Cited by 36
Individual differences in inflammatory and oxidative mechanisms of stress-related mood disorders
Kalinichenko, L. S., Kornhuber, J., & Müller, C. P. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2019.100783 · Cited by 37
Christensen, M. C., McIntyre, R. S., Florea, I., Loft, H., & Fagiolini, A. M. (2021) · CNS Spectrums · doi:10.1017/s1092852921000936 · Cited by 35
“Early optimized antidepressant therapy is likely to afford the best possible treatment outcomes.(7,8) The clinical development program of vortioxetine in MDD included 11 randomized, double-blind, placebo-controlled, fixeddose, short-term studies investigating the efficacy and tolerability of the approved daily doses o…”
BackgroundSelf-citationDepression in the Primary Care Setting
Ellis, P., Kitay, B. M., & Schmidt, C. J. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1903259 · Cited by 34
Levy, I., & Cohen‐Louck, K. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.682122 · Cited by 34
Interpersonal and Social Rhythm Therapy for Patients With Major Depressive Disorder
Crowe, M., Inder, M., Douglas, K. M., Carlyle, D., Wells, H. L., Jordan, J., Lacey, C. J., Mulder, R., Beaglehole, B., & Porter, R. (2019) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.20190024 · Cited by 32
Experience of antidepressant use and discontinuation: A qualitative synthesis of the evidence
Crowe, M., Inder, M., & McCall, C. (2022) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/jpm.12850 · Cited by 32
“Despite these prescribing rates, depression continues to be increasingly prevalent and treatment of depression to full symptomatic and functional recovery remains challenging (Oluboka et al., 2018).”
BackgroundEstimating Severity of Depression From Acoustic Features and Embeddings of Natural Speech
Dumpala, S. H., Rempel, S., Dikaios, K., Sajjadian, M., Uher, R., & Oore, S. (2021) · IEEE International Conference on Acoustics Speech and Signal Processing · doi:10.1109/icassp39728.2021.9414129 · Cited by 25
“Accurate determination of depression severity and its change is key to selecting effective treatment [2].”
BackgroundBaune, B. T., Florea, I., Ebert, B., Touya, M., Ettrup, A., Hadi, M., & Ren, H. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s325954 · Cited by 24
The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder
Arnaud, A. M., Suthoff, E. D., Tavares, R. M., Zhang, X., & Ravindranath, A. J. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01021-w · Cited by 21
“Failure to treat MDD rapidly and effectively to remission may have long-term negative effects [7, 12–16], including lasting effects on patients’ brain structure and function [12, 15], longer depressive episodes and a higher likelihood of relapse [7, 13, 14], and worsened functional outcomes [16, 17].”
BackgroundUher, R., Frey, B. N., Quilty, L. C., Rotzinger, S., Blier, P., Foster, J. A., Müller, D. J., Ravindran, A. V., Soares, C. N., Turecki, G., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20m13229 · Cited by 19
Self-citationKarvelis, P., Charlton, C. E., Allohverdi, S. G., Bedford, P., Hauke, D. J., & Diaconescu, A. O. (2022) · Network Neuroscience · doi:10.1162/netn_a_00233 · Cited by 26
“Positive aspects of mental health (Zimmerman et al., 2006), functional recovery (Greer, Kurian, & Trivedi, 2010; Lam, Parikh, Michalak, Dewa, & Kennedy, 2015; Oluboka et al., 2018), and quality of life (QoL; IsHak et al., 2011)arejustasimportant.”
BackgroundChristensen, M. C., Ren, H., & Fagiolini, A. M. (2022) · Annals of General Psychiatry · doi:10.1186/s12991-022-00392-4 · Cited by 21
Mattingly, G. W., Necking, O., Schmidt, S. N., Reines, E. H., & Ren, H. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2178082 · Cited by 20
Yang, Y. K., Chen, C., Tsai, C.-F., Chang, C., Lai, T.-J., Lee, C.-T., Lin, C., Lan, T., & Herr, K. J. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1980869 · Cited by 19
Pitanupong, J., Sathaporn, K., & Tepsuan, L. (2022) · Annals of General Psychiatry · doi:10.1186/s12991-022-00427-w · Cited by 17
“Therefore, the need to rapidly treat depression to full recovery should be highlighted [8].”
BackgroundClinical benefits of vortioxetine 20 mg/day in patients with major depressive disorder
Christensen, M. C., McIntyre, R. S., Adair, M., Florea, I., Loft, H., & Fagiolini, A. M. (2023) · CNS Spectrums · doi:10.1017/s1092852923002249 · Cited by 15
“The proportions of patients achieving response, sustained response, and remission, as assessed by MADRS total score at weeks 2, 4, 6, and 8, were compared between treatment groups using a logistic regression model with the relevant baseline score as a covariate.”
MethodSelf-citationPapalexi, E., Galanopoulos, A., Kontis, D., Markopoulou, M., Balta, G., Karavelas, E., Panagiotidis, P., Vlachos, T., & Ettrup, A. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04109-5 · Cited by 16
“Early optimized antidepressant dosing is likely to afford the best possible treatment outcomes [3, 5].”
BackgroundRothermund, E., Kilian, R., Balint, E. M., Rottler, E., von Wietersheim, J., Gündel, H., & Holzer, M. S. (2019) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-018-2869-x · Cited by 16
Cao, B., Xu, L., Chen, Y., Wang, D., Lee, Y. L., Rosenblat, J. D., Gao, X., Zhan, S., Sun, F., & McIntyre, R. S. (2021) · CNS Spectrums · doi:10.1017/s1092852921000171 · Cited by 21
“Introduction Major depressive disorder (MDD) is chronic relapsing–remitting brain disorder characterized by both psychological (eg, lowmood, negative thoughts, cognitive dysfunction) and physical (eg, poor sleep, low energy, psychomotor changes) symptoms that are associated with significant functional impairments acro…”
BackgroundInfluentialSelf-citationEfficacy evaluation of serum galectin-3 in hypertension complicated with diastolic dysfunction
Dong, T., Li, H., Wang, S., & Chen, W. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8215 · Cited by 14
Rost, N., Dwyer, D., Gaffron, S., Rechberger, S., Maier, D., Binder, E. B., & Brückl, T. M. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.02.007 · Cited by 16
Fugger, G., Dold, M., Bartova, L., Mitschek, M. M. M., Souery, D., Mendlewicz, J., Serretti, A., Zohar, J., Montgomery, S., Fabbri, C., et al. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa035 · Cited by 17
“Consequently, both diseases need to be sufficiently treated, at best as early as possible in terms of a patient-centered approach as described previously in the literature (Oluboka et al., 2018).”
BackgroundKato, M., Asami, Y., Wajsbrot, D., Wang, X., Boucher, M., Prieto, R., & Pappadopulos, E. A. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.06.011 · Cited by 15
Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis
Katzman, M. A., Wang, X., Wajsbrot, D., & Boucher, M. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119896066 · Cited by 14
Self-citationMolero, P., Ibáñez, Á., de Diego-Adeliño, J., Ramos‐Quiroga, J. A., Dorado, M. G., Rengel, P. M. L., & Sáiz, P. A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03149-z · Cited by 15
Chin, T., Huyghebaert, T., Svrcek, C., & Oluboka, O. J. (2022) · Canadian Family Physician · doi:10.46747/cfp.6811807 · Cited by 15
Self-citationHope and resilience among patients affected by unipolar and bipolar depression
Favale, D., Nacci, M., Bellomo, A., Torales, J. C., Castaldelli-Maia, J. M., & Ventriglio, A. (2023) · International Journal of Social Psychiatry · doi:10.1177/00207640221147166 · Cited by 13
“Pharmacological and psychosocial rehabilitation interventions aim to reduce the personal burden of disease and should be oriented to the achievement of a full-functional recovery which includes the effective control of patient’s psychopathological issues, the improvement of cognitive, personal and social functioning (…”
BackgroundHopwood, M., Scott, E. M., Codyre, D., Barton, D., Puig, A., King, J., Joks, G., & Hickie, I. B. (2024) · Psychiatry Research Communications · doi:10.1016/j.psycom.2024.100177 · Cited by 10
Zhou, J., Xu, J., Feng, Z., Liu, R., Xiao, L., Li, R., Li, X., Zhang, X., Liu, J., Feng, Y., et al. (2025) · Psychological Medicine · doi:10.1017/s0033291725001011 · Cited by 11
“Restoring social functioning is a key indicator of recovery from depression (Oluboka et al., 2018).”
dos Santos, É. N., Molina, M. L., Mondin, T. C., Cardoso, T. D. A., da Silva, R. A., Souza, L. D. D. M., & Jansen, K. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112804 · Cited by 14
Polypharmacy- Purpose, Benefits and Limitations
Grover, D., Tom, M., Maguire, G., & Stahl, S. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220107153813 · Cited by 7
Atkinson, S. D., Thurman, L., Ramaker, S., Buckley, G., Jones, S. R., England, R. D., & Wajsbrot, D. (2018) · CNS Spectrums · doi:10.1017/s1092852918001128 · Cited by 7
“Indeed, evidence from imaging research suggests that MDD may be a progressive disease in which volume loss and circuit dysfunction in brain areas associated with depression increase over the duration of untreated illness.(12) To prevent both neural damage and long-term functional consequences of MDD, early and effecti…”
BackgroundImproving Depression Outcome by Patient-Centered Medical Management
Rush, A. J., & Thase, M. E. (2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.18207 · Cited by 9
Mattingly, G. W., Brunner, E., Chrones, L., Lawrence, D. F. E., Simonsen, K., & Ren, H. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.977560 · Cited by 10
“Therefore, patients place a high level of importance on achieving functional remission with treatment, as well as relieving depressive symptoms (4).”
BackgroundGaspar, F. W., Wizner, K., Morrison, J., & Dewa, C. S. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02731-9 · Cited by 9
Zuilhof, Z., Norris, S., Blondeau, C., Tessier, P., & Blier, P. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s175203 · Cited by 9
“remission rate, and less recurrence of depression than late onset.(14) Thus, starting with more than one medication from treatment initiation may be a worthwhile approach.”
BackgroundSelf-citationLu, W., Tang, X., Huang, C., Wei, M., Bai, C., Fan, X., & Wu, D. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07628-z · Cited by 9
“Delayed diagnosis may not only trigger hippocampal atrophy and prefrontal dysfunction, reducing the effectiveness of antidepressant treatment [8]. but also exacerbate disturbances in neurotransmitter systems (such as serotonin and dopamine), leading to more irreversible biological changes [9].”
Early optimized pharmacological treatment in patients with depression and chronic pain
Oluboka, O. J., Katzman, M. A., Habert, J., Khullar, A., Oakander, M. A., McIntosh, D., McIntyre, R. S., Soares, C. N., Lam, R. W. M., Klassen, L. J., et al. (2022) · CNS Spectrums · doi:10.1017/s1092852922000128 · Cited by 10
“21,71 The CANMAT guideline recommends atypical antipsychotic drugs such as aripiprazole as first-line adjunctive treatment for nonresponse or partial response to an antidepressant monotherapy for symptoms of MDD. 21 If trials of 2 different SNRIs fail, adding a low-dose tricyclic antidepressant (TCA), such as amitript…”
InfluentialSelf-citationAlmeida, S. S., Christensen, M. C., Simonsen, K., & Adair, M. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221132468 · Cited by 7
“The primary outcome of this study – patient functioning – is known to be significantly impaired in patients with MDD, which has a profound impact on daily life and thus is an important treatment goal (Habert et al., 2016; IsHak et al., 2016; Lam et al., 2016; Oluboka et al., 2018; Sheehan et al., 2017).”
BackgroundLapp, M., Quaderi, A., & Corveleyn, X. (2019) · Pratiques Psychologiques · doi:10.1016/j.prps.2018.12.002 · Cited by 8
Why people choose to participate in psychotherapy for depression: A qualitative study
Wells, H. L., Crowe, M., & Inder, M. (2020) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/jpm.12597 · Cited by 7
Polosan, M., Rabbani, M., Christensen, M. C., Simonsen, K., & Ren, H. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s374635 · Cited by 6
Beaudequin, D. A., Can, A., Jones, M., Yang, C., Scherman, J. K., Dutton, M., Schwenn, P., Gallay, C. C., Jensen, E., Hermens, D. F., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114212 · Cited by 7
Dimensions and Predictors of Personal Recovery in Major Depression
Luciano, M., Carmassi, C., & Albert, U. (2022) · Comprehensive approach to psychiatry · doi:10.1007/978-3-030-98301-7_13 · Cited by 8
Ji, I. S., Cheng, M. C. H., Teopiz, K. M., Dri, C. E., Wong, S., Le, G. H., Rhee, T. G., Guillen-Burgos, H. F., Lo, H. K. Y., Zheng, Y. J., et al. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.10.056 · Cited by 8
Self-citationSheehan, J. J., LaVallee, C., Maughn, K., Balakrishnan, S., Pesa, J. A., Joshi, K., & Nelson, C. J. (2023) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2023-0091 · Cited by 5
Inoue, T., Fujimoto, S., Marumoto, T., Kitagawa, T., Ishida, K., Nakajima, T., Moriguchi, Y., Fujikawa, K., & Watanabe, K. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s340309 · Cited by 5
“Second, all patients included in the post hoc analysis had recurrent MDD.”
BackgroundMethodResultInfluentialModerie, C., Nuñez, N., Comai, S., Saint-Laurent, M., Fielding, A., Low, N., & Gobbi, G. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001500 · Cited by 5
“As per clinical guidelines, medications inducing at least a partial response were kept in the pharmacological regimen and an adjuvant or potentiating medicine was then added.(27) All patients had at least mild to severeMDE suggested by a score of 13 or higher on the 17-item Hamilton Depression Rating Scale (HAMD17).”
MethodMa, H.-Y., Wang, X., Huang, X., Yang, C.-J., Sheng, D.-F., Yang, J., & Xu, M. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s307662 · Cited by 5
“In addition to mood symptoms, individuals with MDD experience impairments in physical, occupational and social functioning.(3) High prevalence and recurrence rates of MDD may lead to an increased financial burden on global healthcare system.”
BackgroundKhalil, H., Shajrawi, A. M., Ahmed, F. R., Bani‐Issa, W., Al‐Yateem, N., Shahrour, L. A., Al‐Sharman, A., Subu, M. A., Mottershead, R., Al‐Smadi, A. M., et al. (2025) · International Journal of Orthopaedic and Trauma Nursing · doi:10.1016/j.ijotn.2025.101185 · Cited by 3
Oluboka, O. J., Habert, J., Khullar, A., Robinson, D. J., Katzman, M. A., Klassen, L. J., Soares, C., Chokka, P. R., Oakander, M. A., McIntyre, R. S., et al. (2025) · CNS Spectrums · doi:10.1017/s1092852925000276 · Cited by 3
“15,16 With an “ urgency-to-treat ” (UTT) mindset based on an awareness of the risks of delayed treatment, EOT provides a better opportunity for a full, functional recovery (Supplementary Figure S1).”
InfluentialSelf-citationInitiating Antidepressant Medication: What is the Most Important Factor?
Kasper, S. F. (2022) · Advances in Therapy · doi:10.1007/s12325-021-02028-7 · Cited by 4
Tsuboi, T., Nakayama, T., Horie, J., Tokuda, F., Moriguchi, Y., & Hoshino, T. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06606-9 · Cited by 3
“In more recent, patient-centered approaches to MDD treatment, importance has been placed not only on clinical recovery, but also on personal recovery [2, 3].”
Soares, C. N., Wajsbrot, D., & Boucher, M. (2019) · CNS Spectrums · doi:10.1017/s1092852919000828 · Cited by 3
Schwarz, E., Gündel, H., & Rothermund, E. (2019) · Nervenheilkunde · doi:10.1055/a-0888-7190 · Cited by 5
“[7] Oluboka O, Katzman MA, Habert J et al.”
BackgroundAntidepressant adherence and its predictors in immigrants with depression: A population-based study
Jang, S., Cho, H., Kang, C., & Jang, S. (2020) · Medicine · doi:10.1097/md.0000000000023308 · Cited by 6
“In particular, we focused on patients who were newly prescribed antidepressants because prompt treatment is important for treating depression.([26,27]) To exclude patients who were already undergoing treatment for depression, patients who were diagnosed with depression or prescribed antidepressants within 6 months bef…”
BackgroundChokka, P. R., Hammer-Helmich, L., Schmidt, S. N., Hubert, M., Reines, E. H., & Grande, I. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2503976 · Cited by 2
Sex differences in ketamine treatment for depressive disorders: A systematic review
Feng, Z., Wu, H., Xu, F., Zheng, Y., & Xu, H. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111521 · Cited by 3
Ahern, E., Whiston, A., Kakar, A., Moloney, C., & Slattery, E. J. (2026) · Clinical Psychology Review · doi:10.1016/j.cpr.2026.102744 · Cited by 2
Dumpala, S. H., Dikaios, K., Langley, R., Lowery, A., Oore, S., & Uher, R. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121958 · Cited by 2
Wang, W., Zhang, C., Fan, Y., Yue, S., Yang, Y., Liu, R., Zhang, L., Wang, T., & Fu, F. (2021) · ASN NEURO · doi:10.1177/17590914211052862 · Cited by 3
Kikuchi, T., Iga, J., Oosawa, M., Hoshino, T., Moriguchi, Y., & Izutsu, M. (2024) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12417 · Cited by 2
“7,8 Recently, the concept of emotional blunting (EB) as a symptom of patients with MDD has been proposed.”
BackgroundRecovery-Oriented Treatments in Major Depressive Disorder
Sampogna, G., Vincenzo, M. D., Giallonardo, V., Luciano, M., & Fiorillo, A. (2022) · Comprehensive approach to psychiatry · doi:10.1007/978-3-030-98301-7_14 · Cited by 1
Philippi, R., & Correa, R. (2022) · Revista chilena de neuro-psiquiatría · doi:10.4067/s0717-92272022000300337 · Cited by 2
“Esperar demasiado tiempo antes de dar el siguiente paso, ha demostrado reducir las posibilidades de remisión y recuperación funcional del paciente.(80-82)”
BackgroundHopwood, M., Codyre, D., Barton, D., Scott, E. M., Puig, A., King, J., & Hickie, I. B. (2025) · Research Directions Depression · doi:10.1017/dep.2025.10001 · Cited by 2
“Extended ineffective treatment prolongs the suffering of patients with TRD, diminishes their expectations of treatment effectiveness and potentially contributes to further lack of response (Al-Harbi 2012; Halaris et al. 2021; Leuchter et al. 2009; Malhi et al. 2015; Oluboka et al. 2018).”
Liu, J., Gao, S., Liu, B., Ju, Y., Liao, M., Zhang, L., Li, Z., Zhang, Q., Zhao, X., Tang, H., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103626 · Cited by 1
“8,37,38 Therefore, even modest early benefits may justify timely treatment optimization rather than deferring intervention until more pronounced effects emerge.”
Cheng, N., Li, Y., Zhang, Q., Zhao, Y.-B., Kang, Y., Zhou, Q., & Wu, Z. (2026) · Engineering Research Express · doi:10.1088/2631-8695/ae35d8 · Cited by 1
Veselinović, A. M., Culletta, G., Živković, J. V., Sunaric, S. M., Mitić, Ž. J., Roomi, M. S., & Tutone, M. (2026) · Pharmaceuticals · doi:10.3390/ph19030444 · Cited by 1
“The treatment of MDD is intrinsically complex, typically requiring a combination of psychotherapy and long-term pharmacological intervention [9,10].”
Diagnosis and treatment of depression according to the functional recovery paradigm
Михайлович, У. Г. (2023) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2023-5-79-86 · Cited by 1
Pulido, R. C., & Malatesta, R. P. (2019) · Revista chilena de neuro-psiquiatría · doi:10.4067/s0717-92272019000300306 · Cited by 1
Accidents ischémiques et dépression
Drapier, D. (2022) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2022.04.012 · Cited by 1
Neural mechanisms underlying cognitive inflexibility in obsessive-compulsive disorder: a review
Guo, W., Neo, P. S.-H., & McNaughton, N. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1795436
“This dysfunction contributes to compulsive actions by reinforcing rigid, maladaptive response patterns that resist modi fi cation, thereby reducing cognitive fl exibility, particularly in contexts involving task shifts, feedback adaptation, or updating based on new information (13, 21, 172).”
Molecular Analysis of the Glutathione S-Transferase System in Patients with Depression
dos Anjos, L. R. B., Silveira, L. C., Santos, R. D. S., Machado, V. H., & Reis, Â. A. D. S. (2018) · Multi-Science Journal · doi:10.33837/msj.v1i13.541
Hamati, R. (2020) · uO Research (University of Ottawa) · doi:10.20381/ruor-24287
“Furthermore, a delay in providing effective treatment may reduce the likelihood for remission and full functional recovery, therefore it is of upmost importance to provide early optimized treatment strategies (Oluboka et al., 2018).”
BackgroundKukurbra, K., Manafò, E., Malone, J. L., Drebit, E., Abba‐Aji, A., Oluboka, T., Grauwiler, D., & Petermann, L. (2021) · doi:10.2196/preprints.34160
(2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811351-6.00026-7
Troian, O., & Levada, O. A. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.09.084
Treatment aspects of youth depression with attenuated schizophrenic symptoms
Omelchenko, M. A. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202212205197
Neuropsychic pathology in the context of anterior chest pain
Munteanu, D., Vlase, A., Perţea, L., Felea, M. G., Rusu, A. C., Ciorap, R., & Anton-Prisacariu, B. (2022) · Bulletin of Integrative Psychiatry · doi:10.36219/bpi.2022.3.06
The effectiveness of vortioxetine in patients with depression in real clinical practice
Петрова, Н. Н. (2022) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2022-56-3-113-118
Chin, T., Huyghebaert, T., Svrcek, C., & Oluboka, O. J. (2022) · Canadian Family Physician · doi:10.46747/cfp.6811e301 · Cited by 2
Self-citationHurley, M., Komiti, A., & Hopwood, M. (2024) · Australasian Psychiatry · doi:10.1177/10398562241278959
Yang, Y., Li, H., Khait, A. F. A., & Shellman, J. M. (2026) · Clinical Gerontologist · doi:10.1080/07317115.2026.2738800 · Cited by 1
Kapadia, S., Zhang, Z., Csoboth, C. T., Patel, M., Thase, M. E., & Papakostas, G. I. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf050
“10,33 Real-world evidence supports the early initiation of adjunctive antipsychotic treatment in patients with MDD to reduce healthcare resource use and costs.”
Watanabe, K., Sumiyoshi, T., Kato, M., Kikuchi, T., Moriguchi, Y., Åström, D. O., & Christensen, M. C. (2025) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2025.100955 · Cited by 2
Wang, S., Zhou, W., Feng, H., & Zhang, X. Y. (2025) · Current Psychology · doi:10.1007/s12144-025-08199-8
“This condition correlates with gradual modifica - tions in cerebral architecture and neural network functioning, potentially accounting for its chronicity and disabling characteristics (Oluboka et al., 2017 ).”
Christensen, M. C., Ren, H., & Fagiolini, A. (2022) · Figshare · doi:10.6084/m9.figshare.20106649
Christensen, M. C., Ren, H., & Fagiolini, A. (2022) · Figshare · doi:10.6084/m9.figshare.19518603
Papalexi, E., Galanopoulos, A., Kontis, D., Markopoulou, M., Balta, G., Karavelas, E., Panagiotidis, P., Vlachos, T., & Ettrup, A. (2022) · Figshare · doi:10.6084/m9.figshare.20484658
Yan, C., Wang, J., & Jin, B. (2025) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2025.11.006
Metadata
- Authors
- Oluboka, O. J., Katzman, M. A., Habert, J., McIntosh, D., MacQueen, G. M., Milev, R. V., McIntyre, R. S., & Blier, P.
- Affiliations
- University of Calgary (CA)
- START Clinic (CA)
- University of Toronto (CA)
- University of British Columbia (CA)
- Queen's University (CA)
- University of Ottawa (CA)
- Corresponding author
- Oluboka, Oloruntoba J
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-09-08
- Volume
- 21
- Issue
- 2
- Pages
- 128-144
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC5793729
- OpenAlex
- W2753506619
- Cited by
- 104
- References
- 167
- Citations by year
- 2026: 9 · 2025: 15 · 2024: 3 · 2023: 8 · 2022: 27 · 2021: 14 · 2020: 11 · 2019: 12 · 2018: 5
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Pfizer Canada
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- major depressive disorder, functional recovery, early treatment, pharmacotherapy, measurement-based care, personalized treatment, patient-centered care, treatment delay, brain morphometry, comorbidities, patient preferences
- MeSH terms
- Antidepressive Agents, Major Depressive Disorder, Humans, Patient-Centered Care, Patient Preference, Early Medical Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
